2020 TTF RARE Mutations QA PANEL Clinical Trials for STK11 Mutation

Article and Video CATEGORIES

Cancer Journey

ABOUT

GRACE Videos and Articles

2020 TTF RARE Mutations QA PANEL Clinical Trials for STK11 Mutation

dbrock

Fri, 05/21/2021 - 14:57

2020 Targeted Therapies Patient Forum, Rare Mutations QA PANEL, Clinical Trials for STK11 Mutation

Author

GRACE Videos and Articles

Download Transcript Here

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time. Visit www.cancerGRACE.org for more information!

But meanwhile -- Videos from the 2020 Targeted Therapies Patient Forum are still available!

This past event's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

In this video from the Rare Mutations session from the event, the panel discusses clinical trials for STK11 mutations.

We thank our sponsors for their support of this event! #AstraZeneca #Lilly #Novartis #Takeda #FoundationMedicine #BoehringerIngelheim #BlueprintMedicines #Genentech

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.